CY1111699T1 - Μεθοδος παροχης θεραπειας πιρφενιδονης σε εναν ασθενη - Google Patents

Μεθοδος παροχης θεραπειας πιρφενιδονης σε εναν ασθενη

Info

Publication number
CY1111699T1
CY1111699T1 CY20111100674T CY111100674T CY1111699T1 CY 1111699 T1 CY1111699 T1 CY 1111699T1 CY 20111100674 T CY20111100674 T CY 20111100674T CY 111100674 T CY111100674 T CY 111100674T CY 1111699 T1 CY1111699 T1 CY 1111699T1
Authority
CY
Cyprus
Prior art keywords
therapeas
pirfenidonis
age
providing
pirfenidone
Prior art date
Application number
CY20111100674T
Other languages
Greek (el)
English (en)
Inventor
Williamson Ziegler Bradford
Original Assignee
Intermune, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39259551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111699(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intermune, Inc. filed Critical Intermune, Inc.
Publication of CY1111699T1 publication Critical patent/CY1111699T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J2205/00—General identification or selection means
    • A61J2205/50—General identification or selection means using icons or symbolic figures, e.g. by a graphical representation symbolising the type of pathology or the organ by an image

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
CY20111100674T 2006-12-18 2011-07-12 Μεθοδος παροχης θεραπειας πιρφενιδονης σε εναν ασθενη CY1111699T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87059306P 2006-12-18 2006-12-18
EP07865831A EP2124945B1 (en) 2006-12-18 2007-12-18 Method of providing pirfenidone therapy to a patient

Publications (1)

Publication Number Publication Date
CY1111699T1 true CY1111699T1 (el) 2015-10-07

Family

ID=39259551

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100674T CY1111699T1 (el) 2006-12-18 2011-07-12 Μεθοδος παροχης θεραπειας πιρφενιδονης σε εναν ασθενη

Country Status (14)

Country Link
US (9) US7767700B2 (cg-RX-API-DMAC7.html)
EP (4) EP3053580B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010513320A (cg-RX-API-DMAC7.html)
AT (1) ATE506060T1 (cg-RX-API-DMAC7.html)
CA (1) CA2667654C (cg-RX-API-DMAC7.html)
CY (1) CY1111699T1 (cg-RX-API-DMAC7.html)
DE (1) DE602007014113D1 (cg-RX-API-DMAC7.html)
DK (1) DK2124945T3 (cg-RX-API-DMAC7.html)
ES (3) ES2581844T3 (cg-RX-API-DMAC7.html)
MX (1) MX2009006526A (cg-RX-API-DMAC7.html)
PL (2) PL2124945T3 (cg-RX-API-DMAC7.html)
PT (1) PT2124945E (cg-RX-API-DMAC7.html)
SI (1) SI2124945T1 (cg-RX-API-DMAC7.html)
WO (1) WO2008077068A1 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077068A1 (en) 2006-12-18 2008-06-26 Intermune, Inc. Method of providing pirfenidone therapy to a patient
AU2012205256B2 (en) * 2008-11-10 2015-05-28 Intermune, Inc. Pirfenidone Treatment for Patients with Atypical Liver Function
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
US7566729B1 (en) 2008-11-10 2009-07-28 Intermune, Inc. Modifying pirfenidone treatment for patients with atypical liver function
EP2389227A4 (en) * 2009-01-26 2012-08-08 Intermune Inc METHOD FOR THE TREATMENT OF ACUTE MYOCARDINE CARDS AND ASSOCIATED ILLNESSES THEREOF
US8084475B2 (en) 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
HUE058753T2 (hu) 2011-01-31 2022-09-28 Avalyn Pharma Inc Aeroszol formájú pirfenidon- és piridon-analóg vegyületek és alkalmazásaik
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
CA2819967C (en) * 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
HK1220133A1 (zh) 2013-03-15 2017-04-28 Intermune, Inc. 改善微血管完整性的方法
USD731783S1 (en) 2014-04-16 2015-06-16 Abbvie Inc. Template for a prescription medicine container
USD731171S1 (en) 2013-10-07 2015-06-09 Abbvie Inc. Template for a prescription medicine container
USD731782S1 (en) 2013-10-07 2015-06-16 Abbvie Inc. Template for a prescription medicine container
AU2015204558B2 (en) 2014-01-10 2020-04-30 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
EP3432879B1 (en) * 2016-03-22 2021-01-06 Mayo Foundation for Medical Education and Research Using fatty acid synthase inhibitors to treat fibrosis
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
WO2019028062A1 (en) 2017-07-31 2019-02-07 Washington University PIRFENIDONE DERIVATIVES FOR MODULATION OF B-LYMPHOCYTE ACTIVITY AND PROTECTION OF ORGANS
US11052021B2 (en) 2018-03-22 2021-07-06 Abbvie Inc. Medicine container, method of assembling the container, and method of dispensing the medicine from the container
USD930974S1 (en) 2018-03-22 2021-09-21 Abbvie Inc. Child-resistant medication container
USD930973S1 (en) 2018-03-22 2021-09-21 Abbvie Inc. Child-resistant medication container
USD882243S1 (en) 2018-03-26 2020-04-28 Abbvie Inc. Child-resistant medication container assembly
EP3829632A4 (en) * 2018-07-27 2022-05-04 Société des Produits Nestlé S.A. Oral immunotherapy unit dose dispensing systems and methods
WO2021110805A1 (en) 2019-12-04 2021-06-10 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
GB2589635B (en) * 2019-12-06 2021-12-01 Merxin Ltd Elongate form medicament carrier and medicament dispenser
CN117042738A (zh) * 2021-03-17 2023-11-10 埃科特莱茵药品有限公司 药物剂量系统
WO2023161668A1 (en) 2022-02-28 2023-08-31 Nuformix Technologies Limited Compositions and methods for treatment of idiopathic pulmonary fibrosis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US695044A (en) * 1901-12-28 1902-03-11 Albert E Gibson Non-refillable bottle.
SE9502370D0 (sv) 1995-06-30 1995-06-30 Astra Ab Blister pack, especially for drugs, as well as method and device in manufacturing the same
US6956044B1 (en) * 2000-02-21 2005-10-18 Margolin Solomon B Compositions and methods for treatment of epilepsy
ATE452637T1 (de) * 2001-01-29 2010-01-15 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1- phenyl-2-(1h)-pyridon enthält
WO2004019863A2 (en) * 2002-08-28 2004-03-11 Intermune, Inc. Combination therapy for treatment of fibrotic disorders
US7413749B2 (en) * 2003-03-11 2008-08-19 Purdue Pharma L.P. Titration dosing regimen for controlled release tramadol
CA2525647A1 (en) * 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
US20070092488A1 (en) * 2003-05-16 2007-04-26 Intermune Inc. Methods of treating idiopathic pulmonary fibrosis
WO2005000227A2 (en) * 2003-06-06 2005-01-06 Intermune, Inc. Methods of treating tnf-mediated disorders
US20070053877A1 (en) * 2003-08-21 2007-03-08 Intermune, Inc. Methods of treating idiopathic pulmonary fibrosis
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
EP2305697A3 (en) * 2005-07-25 2011-07-27 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
US20070203202A1 (en) * 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy
US20080003635A1 (en) * 2006-06-12 2008-01-03 Intermune, Inc. High Throughput Collagen Synthesis Assay
ATE533486T1 (de) * 2006-06-15 2011-12-15 Shanghai Genomics Inc Verwendung von pyridonderivaten zur vorbeugung und behandlung von strahlungsbedingter lungenverletzung
RU2008152171A (ru) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
WO2008077068A1 (en) 2006-12-18 2008-06-26 Intermune, Inc. Method of providing pirfenidone therapy to a patient
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
WO2008144720A2 (en) * 2007-05-21 2008-11-27 University Of Washington Inhibitors of igf-1r signaling for the treatment of respiratory disorders

Also Published As

Publication number Publication date
ES2581844T3 (es) 2016-09-07
EP3053580B1 (en) 2021-06-30
ES2395396T3 (es) 2013-02-12
PT2124945E (pt) 2011-07-01
EP2124945B1 (en) 2011-04-20
EP3053580A1 (en) 2016-08-10
US20090197923A1 (en) 2009-08-06
MX2009006526A (es) 2009-06-30
CA2667654A1 (en) 2008-06-26
US20190247380A1 (en) 2019-08-15
US20080194644A1 (en) 2008-08-14
PL3053580T3 (pl) 2021-12-20
US7767700B2 (en) 2010-08-03
US20100324097A1 (en) 2010-12-23
EP2338489A1 (en) 2011-06-29
DE602007014113D1 (de) 2011-06-01
US20180140588A1 (en) 2018-05-24
US8420674B2 (en) 2013-04-16
HK1153647A1 (en) 2012-04-05
EP2471534A1 (en) 2012-07-04
JP2010513320A (ja) 2010-04-30
DK2124945T3 (da) 2011-08-01
US20160324842A1 (en) 2016-11-10
US7696236B2 (en) 2010-04-13
SI2124945T1 (sl) 2011-08-31
ES2882956T3 (es) 2021-12-03
PL2124945T3 (pl) 2011-09-30
EP2338489B1 (en) 2016-04-27
CA2667654C (en) 2016-12-13
EP2124945A1 (en) 2009-12-02
WO2008077068A1 (en) 2008-06-26
HK1133584A1 (en) 2010-04-01
US20190000821A1 (en) 2019-01-03
US20130220871A1 (en) 2013-08-29
ATE506060T1 (de) 2011-05-15
US20200113884A1 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
CY1111699T1 (el) Μεθοδος παροχης θεραπειας πιρφενιδονης σε εναν ασθενη
PH12015500719A1 (en) Gdf-8-inhibitors
WO2008144241A3 (en) Altering pharmacokinetics of pirfenidone therapy
CY1123426T1 (el) Μεθοδος για τη ληψη κρυσταλλων αλατος μεγλουμινης του 1-(5,6-διχλωρο-1η-βενζο[d]ιμιδαζολ-2-υλο)-1η-πυραζολο-4-καρβοξυλικου οξεος
CY1115862T1 (el) Θεραπεια με πιρφενιδονη για ασθενεις με μη φυσιολογικη ηπατικη λειτουργια
EA201101507A1 (ru) Способы лечения солидных опухолей
MX346186B (es) Inhibidores de proteina cinasas.
UA117556C2 (uk) Спосіб збільшення ефективності терапевтичного засобу шляхом введення метотрексату
EA201490269A1 (ru) Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
IN2009KN03959A (cg-RX-API-DMAC7.html)
MX2010002736A (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de tinnitus coclear.
BR112012032796A2 (pt) miméticos niacina, e os métodos de utilização dos mesmos
CY1114492T1 (el) Συνδυασμος αλφα 7 νικοτινικων αγωνιστων και αντιψυχωσικων
HK1231381A1 (zh) 癌症组合疗法
BR112015002183A2 (pt) processos para a preparação de (s) -3- (4 - ((4- (morfolinometil) benzil) oxi) -1-oxoisoindolin-2-il) -piperidina-2,6-diona e formas farmaceuticamente aceitáveis da mesma
EA201190337A1 (ru) Способ лечения
PH12014500381A1 (en) Therapeutic methods
WO2012002773A3 (en) Phenylcarbamate compound and muscle relaxant containing the same
AU2018333954A1 (en) Methods and compositions to inhibit dependence on opioids
CY1111919T1 (el) Ηλεκτρικο αλας της 2-((4-(1-μεθυλ-4-(πυριδιν-4-υλ)-1η-πυραζολ-3-υλ)-φαινοξυ)μεθυλ)κινολινης
TR201905655T4 (tr) 4-amino-3-kloro-6-(4-kloro-2-floro-3-metoksifenil)-5-floropiridin-2-karboksilik asit veya bunun bir türevi ve diflufenikan veya pikolinafen içeren herbisidal bileşimler.
MX2011012538A (es) Terapia de combinacion para el tratamiento del mieloma multiple.
EA201200319A1 (ru) Введение активированного угля при оказании неотложной помощи в случае передозировки этексилата дабигатрана
MX2014003867A (es) Tratamiento de rinitis.